2 hrs ago
Claroid Pharmaceuticals Files DRHP For IPO-Funded Ahmedabad Facility
Claroid Pharmaceuticals wants to sell shares to the public through an IPO.
It has submitted its draft IPO documents to Sebi.
Some shares will be newly issued by the company, while other shares will be sold by existing shareholders.
The company plans to use money from the new shares to build a factory in Ahmedabad.
The factory will make several types of medicines, including injections and eye drops.
It is expected to cost about ₹167.97 crore.
The factory is planned to make 15 lakh units each month.
Claroid already makes tablets, capsules and ointments and sells medicines in several African markets.
Claroid Pharmaceuticals filed draft IPO papers with Sebi to raise funds.
The proposed IPO includes up to 74.50 lakh new shares and 51.50 lakh shares offered for sale.
IPO proceeds will help finance a ₹167.97-crore manufacturing facility in Ahmedabad.
The new plant will produce injectables, ampoules, vials, dry powder, pre-filled syringes and eye drops.
The company’s revenue rose from ₹62.98 crore in FY24 to ₹169.72 crore in FY26.
- Who
- Claroid Pharmaceuticals, a Gujarat-based pharmaceutical formulations manufacturer.
- What
- The company filed a DRHP with Sebi for a proposed IPO comprising fresh shares and an offer for sale.
- Where
- The proposed manufacturing facility will be built on the company’s existing land in Ahmedabad, Gujarat.
- When
- September 23.
- Why
- To raise funds for capital expenditure on a new pharmaceutical manufacturing facility.
Key facts
- Fresh issue
- Up to 74.50 lakh equity shares
- Offer for sale
- Up to 51.50 lakh equity shares
- Facility cost
- Approximately ₹167.97 crore
- Planned capacity
- 15 lakh units per month
- Existing operations
- Claroid manufactures tablets, capsules and ointments at Pirana, Ahmedabad.
- Formulations developed
- 129 pharmaceutical formulations across multiple therapeutic segments
- Revenue growth
- Revenue from operations increased from ₹62.98 crore in FY24 to ₹169.72 crore in FY26










